Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) have become an important treatment option for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of pseudoprogression (PsP) and treatment beyond RECIST1.1-defined progressive disease (TBP) on outcome in NSCLC patients treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Sang Eun, Park, Hyo Jung, Byun, Sangil, Pyo, Junhee, Kim, Jwa Hoon, Choi, Chang-Min, Lee, Jae Cheol, Lee, Dae Ho, Kim, Sang-We, Yoon, Shinkyo, Kim, Kyung Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458612/
https://www.ncbi.nlm.nih.gov/pubmed/32923136
http://dx.doi.org/10.1080/2162402X.2020.1776058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458612/
https://www.ncbi.nlm.nih.gov/pubmed/32923136
http://dx.doi.org/10.1080/2162402X.2020.1776058

Ejemplares similares